New Paradigms in Chronic Myelogenous Leukemia

FDA Safety Alert
UPDATED 12/20/2013. Ponatinib has been reinstated by the US FDA with update to the labeling and a REMS program. Read More Here U.S. Resumption of Marketing and Commercial Distribution of Ponatinib in Refractory Philadelphia-Positive Leukemias

Supplemental Resource (not required for credit): Evolving Principles of CML Management 2012/2013
Eric J. Feldman, MD